NEW YORK, June 18 /PRNewswire/ -- Danube Pharmaceuticals, Inc., a privately held biopharmaceutical company specializing in the commercial research and development of innovative drugs for ophthalmology, is pleased to announce the appointment of Dr. Barrett Katz, MD, MBA as its Chief Executive Officer.
"I am honored and delighted to join Danube Pharmaceuticals at this inflection point in its history as it advances its lead programs through clinical trials and brings novel bench research to the clinics and bedside," said Barrett Katz, MD, MBA, Chief Executive Officer of Danube.
"We are delighted to welcome Dr. Katz to our team," said David R. Guyer, MD, Chairman of Danube. "His leadership, energy and experience will transform our senior management team and complement the clinical and managerial talents we have. His outstanding reputation in the international ophthalmology community coupled with his expertise in the field of drug development, drug approval and product launch will be invaluable for bringing Danube's product candidates from clinical trials to market effectively and efficiently."
Dr. Katz is a renowned ophthalmologist with over 25 years of experience in clinical trials and medical strategy, drug development and regulatory issues. Prior to joining Danube, Dr. Katz served as Executive Vice President and Chief Medical Officer of Fovea Pharmaceuticals SA, in Paris. Before that he was Vice President for Medical Affairs and Medical Strategy at Eyetech Pharmaceuticals, and had been integral to the team that developed Macugen(TM) and brought it to market.
Dr. Katz also served as Professor of Ophthalmology, Neurology and
Neurosurgery, and as the Chairman of the Department of Ophthalmology at The
George Washington University School of Medicine in Washington, D.C. While
there, he formulated and sponsored a joint fellowship in Ophthalmology drug
development, clinical trials, and regulatory affairs with the U.S. Food and
|SOURCE Danube Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved